Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo – 2 February 2015 – Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects.